This procedural ruling removes a near-term risk of claim narrowing and keeps Lilly's case against a key compounder of unapproved tirzepatide on track for discovery. Monitor for summary judgment motions or settlement developments, as a favorable outcome could protect Lilly's GLP-1 franchise revenue from compounding competition through the exclusivity period.
Price Chart
Executive Summary
The court denied Empower Pharmacy's motion to require Eli Lilly to file a reply addressing state-law regulatory exemption defenses. The ruling is a procedural win for Lilly, allowing its state-law unfair competition claims (Alaska, Colorado, Connecticut, Hawaii, North Carolina, South Carolina, Tennessee, Washington) to proceed toward discovery without additional pleading burdens. This keeps Lilly's case against a compounder of unapproved tirzepatide products on track, preserving the potential for injunctive relief and damages related to lost sales of Mounjaro and Zepbound through at least May 2027 market exclusivity.
Court Ruling Details
Key Facts
- Empower's motion to require a Rule 7(a)(7) reply was DENIED.
- Lilly's state-law unfair competition claims under the laws of eight states survive and will proceed to discovery.
- The court found Empower's arguments were a rehash of its already-denied motion to dismiss and that Lilly's complaint is 'far from barebones.'
- Lilly's tirzepatide products (Mounjaro, Zepbound) have FDA market exclusivity through at least May 2027.
- The case concerns Empower's compounding and sale of unapproved tirzepatide medications, which Lilly alleges causes lost sales and brand harm.
Financial Impact
No damages awarded in this procedural ruling. Lilly seeks injunctive and monetary relief for lost sales from Empower's alleged unfair competition; the amount is not stated in the document.
Risk Factors
- Empower may still prevail on the merits of its regulatory exemption defenses at summary judgment or trial.
- The case is in early stages; discovery costs and duration are uncertain.
- Appeal of this procedural ruling is unlikely but possible.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 court opinion from CourtListener.
| Document | Accession Number |
|---|---|
| COURT-RULING Data (Synthetic) | court-582475d778-LLY |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Sep 11, 2026 21d ago | Press Release | $1,115.70 $1,152.93 | ▲ +3.34% | ▲ +3.56% | $1,142.85 (+2.43%) |
Sep 8, 2026 24d ago | Court Ruling | $1,123.91 $1,138.28 | ▲ +1.28% | ▲ +1.94% | $1,142.85 (+1.69%) |
Aug 18, 2026 6w ago | Insider Cluster | $1,225.73 $1,233.66 | ▲ +0.65% | ▲ +0.85% | $1,142.85 (−6.76%) |
Aug 11, 2026 7w ago | Insider Cluster | $1,215.02 $1,225.73 | ▲ +0.88% | ▲ +1.29% | $1,142.85 (−5.94%) |
Aug 7, 2026 8w ago | Court Ruling | $1,185.71 $1,180.16 | ▼ −0.47% | ▼ −0.87% | $1,142.85 (−3.61%) |
Aug 5, 2026 8w ago | 8-K | $1,169.86 $1,220.28 | ▲ +4.31% | ▲ +3.96% | $1,142.85 (−2.31%) |
Aug 4, 2026 8w ago | Court Ruling | $1,115.68 $1,215.02 | ▲ +8.90% | ▲ +9.00% | $1,142.85 (+2.44%) |
Jul 31, 2026 9w ago | Court Ruling | $1,148.84 $1,185.71 | ▼ −3.21% | ▲ +0.30% | $1,142.85 (+0.52%) |
Jul 30, 2026 9w ago | Court Ruling | $1,154.97 $1,191.94 | ▲ +3.20% | ▼ −0.42% | $1,142.85 (−1.05%) |
Jul 22, 2026 10w ago | Press Release | $1,163.01 $1,210.02 | ▲ +4.04% | ▲ +6.44% | $1,142.85 (−1.73%) |
US Market Status
Subscribe to SecBot
Get Real-Time Court Ruling Intelligence
Market-moving court rulings analyzed within minutes. Patent verdicts, antitrust decisions, class certifications, and more — parsed and scored by AI.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access